Unknown PHASE1 INTERVENTIONAL 1-arm NCT01847118

A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Conditions Advanced Solid Tumors Metastatic Solid Tumors

Interventions Sevacizumab

Updated 5 times since 2017 Last updated: Mar 22, 2015 Started: Apr 30, 2013 Primary completion: Nov 30, 2015 Completion: Nov 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Solid Tumors and Metastatic Solid Tumors and is currently ongoing. Jiangsu Simcere Pharmaceutical Co., Ltd. leads this study, which shows 5 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu Simcere Pharmaceutical Co., Ltd.

Data source: Jiangsu Simcere Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China